할로자임 테라퓨틱스 (HALO) 주가 전망: 목표주가, 배당, 최신 뉴스

Halozyme Therapeutics, Inc. , a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy.

The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy.

It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. ; Takeda Pharmaceuticals International AG and Baxalta US Inc. ; Pfizer Inc. ; Janssen Biotech, Inc. ; AbbVie, Inc. ; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co. , Ltd. ; Acumen Pharmaceuticals, Inc. ; Merus N. V. ; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.

Halozyme Therapeutics, Inc.는 미국, 스위스, 벨기에, 일본 등에서 독점 효소 및 장치를 연구·개발·상용화하는 바이오제약회사입니다. 회사의 핵심 기술은 특허 받은 재조합 인간 히알루로니다아제(재조합 인간 히알루로니다아제, rHuPH20)로, 단클론항체 등 주사형 생물의약품과 기타 치료제, 소분자 및 체액의 전달을 가능하게 합니다.

주요 제품으로는 rHuPH20 제형인 Hylenex recombinant(피하주사(SC) 시 약물의 확산·흡수를 촉진하고 조영제의 흡수를 돕는 제제)와 남성 테스토스테론 대체요법용 SC 주사제 XYOSTED가 있습니다. 또한 Herceptin Hylecta(trastuzumab), Phesgo(유방암 치료), Mabthera SC(만성 림프구성 백혈병), Tecentriq SC(IV 주입), Ocrevus SC(다발성 경화증), HYQVIA(원발성 면역결핍 질환), DARZALEX(아밀로이드증 및 잠복·다발성 골수종), epinephrine Injection(알레르기 반응), nivolumab 및 relatlimab(전이성 또는 절제가 불가능한 흑색종), 테리파라타이드 주사, ARGX-113 및 ARGX-117(다초점 운동성 신경병증 등 중증 자가면역질환 치료) 등을 제공합니다.

Halozyme는 F. Hoffmann‑La Roche, Ltd. 및 Hoffmann‑La Roche, Inc., Takeda Pharmaceuticals International AG 및 Baxalta US Inc., Pfizer Inc., Janssen Biotech, Inc., AbbVie, Inc., Eli Lilly and Company, Bristol Myers Squibb Company, argenx BVBA, ViiV Healthcare, Chugai Pharmaceutical Co., Ltd., Acumen Pharmaceuticals, Inc., Merus N.V., Skye Bioscience, Inc. 등과 협업 및 라이선스 계약을 체결하고 있습니다. 회사는 1998년에 설립되었으며 본사는 캘리포니아주 샌디에이고에 위치해 있습니다.

• 주소: 12390 El Camino Real, San Diego, CA 92130, United States

• 전화번호: 858 794 8889

• 웹사이트: https://halozyme.com

• 섹터: Healthcare

• 산업: Biotechnology

• 직원 수: 423